Figure 3From: Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece Probability that agomelatine is cost-effective against branded comparators at alternative monetary values of a quality-adjusted-life-year, when both direct health care costs and indirect costs were considered in the analysis. Back to article page